Cerebrolysin is a peptide preparation mimicking the action of neurotrophic factors and has beneficial effects on neurodegenerative diseases and stroke. The present study investigated the effect of Cerebrolysin on neurogenesis in a rat model of embolic middle cerebral artery occlusion (MCAo). Treatment with Cerebrolysin at doses of 2.5 and 5 ml/kg significantly increased the number of bromodeoxyuridine-positive (BrdU 1 ) subventricular zone (SVZ) neural progenitor cells and doublecortin (DCX) immunoreactivity (migrating neuroblasts) in the ipsilateral SVZ and striatal ischemic boundary 28 days after stroke when the treatment was initiated 24 hr after stroke. The treatment also reduced TUNEL 1 cells by 50% in the ischemic boundary. However, treatment with Cerebrolysin at a dose of 2.5 ml/kg initiated at 24 and 48 hr did not significantly reduce infarct volume but substantially improved neurological outcomes measured by an array of behavioral tests 21 and 28 days after stroke. Incubation of SVZ neural progenitor cells from ischemic rats with Cerebrolysin dose dependently augmented BrdU 1 cells and increased the number of Tuj1 1 cells (a marker of immature neurons). Blockage of the PI3K/Akt pathway abolished Cerebrolysin-increased BrdU 1 cells. Moreover, Cerebrolysin treatment promoted neural progenitor cell migration. Collectively, these data indicate that Cerebrolysin treatment when initiated 24 and 48 hr after stroke enhances neurogenesis in the ischemic brain and improves functional outcome and that Cerebrolysin-augmented proliferation, differentiation, and migration of adult SVZ neural progenitor cells contribute to Cerebrolysin-induced neurogenesis, which may be related to improvement of neurological outcome. The PI3K/Akt pathway mediates Cerebrolysin-induced progenitor cell proliferation. V V C 2010 Wiley-Liss, Inc.
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Key words: Cerebrolysin; neurogenesis; MCAO; rats Cerebrolysin is a peptide preparation, which exerts beneficial effects on neurodegenerative diseases and stroke (Tatebayashi et al., 2003; Rockenstein et al., 2007) . Preclinical studies have shown that acute treatment with Cerebrolysin reduces cerebral infarction in rats after transient ischemia, and delayed administration of Cerebrolysin promotes neurological functional recovery without reducing lesion volume (Ren et al., 2007; Hanson et al., 2009) . These data suggest that, in addition to the neuroprotective effect, Cerebrolysin has a capacity to promote brain repair after stroke.
In adult rodent brain, new neurons are generated in the subgranular zone of the dentate gyrus and the subventricular zone (SVZ) of the lateral ventricle (Alvarez-Buylla et al., 2000; Gage, 2002) . Cerebrolysin enhances dentate gyrus neurogenesis in normal rat and in mouse models of Alzheimer's disease (AD; Tatebayashi et al., 2003; Rockenstein et al., 2007) and promotes adult hippocampal progenitor cells to differentiate into neurons in vitro (Chen et al., 2007) . Neurogenesis enhanced by Cerebrolysin is related to improvement of behavioral performance and spatial memory (Tatebayashi et al., 2003) . Stroke induces neurogenesis in the SVZ, and newly generated neuroblasts in the SVZ migrate to the ischemic boundary to replace damaged neurons (Jin et al., 2001; Zhang et al., 2001; Arvidsson et al., 2002) . Enhancement of neurogenesis in the ischemic brain promotes brain remodeling and is correlated with neurological outcome (Zhang and Chopp, 2009) . However, the effect of Cerebrolysin on neurogenesis in ischemic brain has not been fully investigated. In the present study, we examined whether Cerebrolysin affects stroke-induced neurogenesis in a rat model of embolic middle cerebral artery occlusion (MCAo) and we directly measured the effect of Cerebrolysin on SVZ neural progenitor cells in vitro.
MATERIALS AND METHODS
All experimental procedures were approved by the Institutional Animal Care and Use Committee of Henry Ford Hospital.
Animal Model
Male Wistar rats weighing 350-450 g were employed. The middle cerebral artery (MCA) was occluded by placement of an embolus at its origin (Zhang et al., 1997) .
Experimental Protocols
Cerebrolysin or vehicle was intraperitoneally (i.p.) injected daily for 21 days, starting at 24 hr after MCAo. To label mitotic cells, bromodeoxyuridine (BrdU; 100 mg/kg; Sigma, St. Louis, MO) was administered i.p. daily for 7 consecutive days starting at 24 hr after stroke. 1) To examine the dose responses of Cerebrolysin, 24 hr after MCAo, rats were randomly assigned to 1.0, 2.5, and 5.0 ml/kg Cerebrolysin groups or vehicle group (n 5 10/group). 2) To examine the therapeutic window of Cerebrolysin, ischemic rats were randomly treated with Cerebrolysin at a dose of 2.5 ml/kg starting at 48, 72, or 96 hr after stroke onset (n 5 10/group). These animals were killed 28 days after MCAo. 3) To examine the direct effect of Cerebrolysin on neural progenitor cells, SVZ neural progenitor cells were isolated from nonischemic rats (n 5 5) or rats subjected to 7 days of MCAo (n 5 5).
Behavioral Tests
All behavioral tests were performed by observers blinded to the treatments 1, 7, 14, 21, and 28 days after onset of MCAo.
Foot-Fault Test
A modified foot-fault test was employed to measure forelimb placement dysfunction (Zhang et al., 2002) . The total number of steps (movement of each forelimb) that the rat used to cross the grid and the total numbers of foot faults for left forelimb were recorded.
Adhesive-Removal Test
An adhesive-removal test was employed to measure somatosensory deficits (Schallert et al., 1982; Zhang et al., 2002) . The mean time required to remove both stimuli from limbs was recorded.
Modified Neurological Severity Score (mNSS)
Rats were tested for motor, sensory, reflex, and balance dysfunctions with the mNSS (Chen et al., 2001) . Neurological function was graded on a scale of 0 to 18 (normal score, 0; maximal deficit score, 18).
Histopathology and Immunohistochemistry
Infarct volume was measured on seven hematoxylin and eosin (H&E)-stained coronal sections using the microcomputer imaging device (MCID) system (Imaging Research, St. Catharines, Ontario, Canada), as previously described (Zhang et al., 1997) . For immunostaining, a series of coronal sections at bregma -0.4 to -1.4 mm was prepared. The following antibodies were used: mouse anti-BrdU (1:100; Boehringer Mannheim, Indianapolis, IN), goat antidoublecortin (DCX; 1:200; Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-b-tubulin III (TuJ-1; 1:500; Covance, Detroit, MI), and rabbit antiglial fibrillary acidic protein (GFAP; 1:500; Dako Cytomation, Carpinteria, CA). The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) method (In Situ Apoptosis Detection Kit; Chemicon, Temecula, CA) was used to assess apoptotic cells.
SVZ Neural Progenitor Cell Culture
Neural progenitor cells were isolated from the SVZ, as previously described . To generate neurospheres, SVZ cells were plated at a density of 2 3 10 4 cells/ ml in the presence growth medium . The growth medium contains Dulbecco's modified Eagle's (DMEM)-F12 medium (Invitrogen, Carlsbad, CA), 20 ng/ml of epidermal growth factor (EGF; R&D Systems, Minneapolis, MN), and 20 ng/ml basic fibroblast growth factor (bFGF, R&D Systems). DMEM-F-12 medium contains L-glutamine (2 mM), glucose (0.6%), putrescine (9.6 lg/ml), insulin (0.025 mg/ml), progesterone (6.3 ng/ml), apotransferrin (0.1 mg/ml), and sodium selenite (5.2 ng/ml). To examine the effect of Cerebrolysin on neural progenitor cell proliferation, the generated neurospheres (primary sphere) were passaged by mechanical dissociation and then plated directly onto laminincoated glass coverslips in growth medium with different doses (0, 5, 10, and 20 ll/ml) of Cerebrolysin for 7 days. BrdU (30 lg/ml) was added 24 hr before the termination of incubation. To identify cell proliferation, cultured cells were immunostained with an antibody against BrdU and were counterstained with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA).
To examine the effect of Cerebrolysin on neural progenitor cell differentiation, neurospheres were mechanically dissociated and then plated directly onto laminin-coated glass coverslips in DMEM-F-12 medium containing 2% FBS and Cerebrolysin at concentrations of 0, 5, 10, and 20 ml/ml medium, but without the growth factors, for 7 days. To determine cell phenotypes, cultured cells were immunostained with antibodies against TuJ1 (a marker of immature neurons) and GFAP (a marker of astrocytes).
To measure neural progenitor cell motility, a single neurosphere (200 lm diameter) derived from nonischemic rats was seeded in reduced-growth factor medium containing Matrigel (40 ll; BD Biosciences, Franklin Lakes, NJ), in the presence or absence of Cerebrolysin at doses of 5, 10, and 20 lg/ml. The distance of cells that migrate out of the neurosphere was recorded 72 hr after incubation (Robin et al., 2006; Wang et al., 2006) .
To examine whether the PI3K/Akt signaling pathway is involved in the effect of Cerebrolysin on neurogenesis, neural progenitor cells were left untreated or pretreated with LY294002 (10 lM), a PI3K-Akt inhibitor, for 1 hr, followed by treatment with or without Cerebrolysin (10 ml/ml) for 1 hr and 7 days for measurements of Akt and cell proliferation, respectively. Levels of Akt were measured using Western blot analysis.
Statistical Analysis
Data were evaluated for normality, and the data transformation was performed if data were not normal. As a result, the behavior tests were not normal, and ranked data were used for the analysis. The global test using generalize estimating equation (GEE) was employed to test the group difference on functional recovery measured from multiple behavior tests (Lu et al., 2003) . The analysis began testing the overall dose effect, followed by pairwise dose group comparisons if the overall dose effect was detected at the 0.05 level. Data are presented as mean 6 SE.
RESULTS

Effect of Cerebrolysin on Neurological Outcome
To examine the effect of Cerebrolysin on neurological outcome, an array of behavioral tests was performed. All rats exhibited severe neurological deficits as measured by mNSS, foot-fault, and adhesive-removal tests 24 hr after stroke onset, and there were no significant differences among the groups (Fig. 1) . Treatment with Cerebrolysin initiated 24 hr poststroke with doses of 2.5 and 5 ml/kg significantly improved performance on mNSS, foot-fault, and adhesive-removal tests starting 21 days and persisting to at least 28 days after stroke compared with vehicle-treated rats (Fig. 1) . Interestingly, rats treated with Cerebrolysin at the dose of 1 ml/kg exhibited a significant improvement of foot-fault score 28 days after stroke (Fig. 1) . These data indicate that Cerebrolysin dose dependently improves neurological outcome. To examine whether further delayed treatment with Cerebrolysin has an effect on neurological outcome, we treated ischemic rats with Cerebrolysin (2.5 ml/kg) 48, 72, and 96 hr after stroke. Delayed treatment with Cerebrolysin starting at 48 hr but not at 72 or 96 hr poststroke significantly improved performance on foot-fault and adhesive-removal tests at 21 and 28 days after stroke and mNSS at 28 days compared with the saline-treated rats (Fig. 1) . These data suggest that Cerebrolysin at a dose of 2.5 ml/kg has a therapeutic window of 48 hr in this model. Cerebrolysin treatment did not significantly reduce infarct volume among experimental groups (Table I) .
Effect of Cerebrolysin on Neurogenesis In Vivo
The results that Cerebrolysin improved functional outcome without a significant reduction in ischemic lesion volume suggest that mechanisms other than the neuroprotection may contribute to the observed functional improvement. Cerebrolysin induces neurogenesis in the dentate gyrus of adult rodent brain (AlvarezBuylla et al., 2000; Gage, 2002) , and neurogenesis is related to neurological function (van Praag et al., 1999) . & 1 ml/kg, 24 hr; *2.5 ml/kg, 24 hr; # 5 ml/kg, 24 hr; **2.5 ml/kg, 48 hr P < 0.05 vs. the vehicle group (n 5 10/group). To examine the effect of Cerebrolysin on neurogenesis in the SVZ, which contains neural stem cells (AlvarezBuylla et al., 2000) , proliferated SVZ cells identified by BrdU-positive cells and neuroblasts detected by DCX immunoreactive cells were measured 28 days after stroke in animals treated with different doses of Cerebrolysin starting 24 hr after stroke. Treatment with Cerebrolysin at doses of 2.5 and 5 ml/kg, but not 1 ml/kg, significantly increased the number of BrdU-positive cells (Fig.  2I ) and the DCX-immunoreactive area in the ipsilateral SVZ ( Fig. 2A-J ) compared with saline-treated rats when the treatment was initiated at 24 hr after stroke onset. In addition, Cerebrolysin substantially increased the number of DCX-positive cells in the striatal ischemic boundary region (Fig. 2D,J) . Double immunostaining revealed that DCX-positive cells in the ischemic boundary were BrdU positive (Fig. 2G,H) , indicating neurogenesis. Most new neurons die in the ischemic boundary (Arvidsson et al., 2002) . To examine whether the increase of neuroblasts by Cerebrolysin results from the effect of Cerebrolysin on the reduction of apoptotic cell death, we measured the number of TUNEL-positive cells in the SVZ and ischemic boundary region. Treatment with Cerebrolysin at 1, 2.5, and 5 ml/kg reduced the number of TUNEL-positive cells by 50% in the ischemic boundary (P < 0.05; Fig. 2K ) but did not significantly reduce the number of TUNEL-positive cells in the SVZ (Fig. 2K) . Collectively, these data indicate that Cerebrolysin enhances neurogenesis in the ischemic brain.
Effect of Cerebrolysin on SVZ Neural Progenitor Cells In Vitro
To examine the effects of Cerebrolysin on neural progenitor cells directly, we performed a neurosphere 1 cell (green) in the ischemic striatum was BrdU 1 (red; merged, arrow). H: Orthogonal view of a DCX 1 (green) and BrdU 1 (red) cell. I-K: Quantitative data of BrdU (I), DCX (J) and TUNEL (K) cells in different experimental groups (n 5 10/group). *P < 0.05 vs. the vehicle group. Control, saline; LV, lateral ventricle. Scale bars 5 100 lm in F; 10 lm in G.
assay in which neural progenitor cells were isolated from nonischemic or ischemic rats . When they are cultured with bFGF and EGF, the primary neural progenitor cells proliferate, whereas with withdrawal of the growth factors, the neural progenitor cells differentiate into neurons and glial cells . Treatment of nonischemic or ischemic progenitor cells with Cerebrolysin at 10 and 20 ll/ml medium, respectively, significantly increased the number of BrdUpositive cells 7 days after incubation (Fig. 3A-E) . In addition, incubation of ischemic progenitor cells with Cerebrolysin at a dose of 20 ll/ml almost doubled the number of Tuj1-positive cells from 9.6% in the control to 18.1% in the Cerebrolysin group (Fig. 3F-J) .
Although Cerebrolysin at doses of 10 and 20 ll/ml increased the number of Tuj1-positive cells in the nonischemia-derived progenitor cells, it did not reach a statistical significance (Fig. 3J) . Cerebrolysin did not significantly increase the number of GFAP-positive cells (Fig. 3K-O) . These data provide direct evidence that Cerebrolysin dose dependently enhances neurogenesis, which is consistent with in vivo results.
In vivo findings that an increase in DCX-positive cells in the ischemic boundary suggest that Cerebrolysin may promote migration of neuroblasts in the SVZ to the ischemic boundary. We, therefore, examined the effect of Cerebrolysin on neural progenitor cell motility. When a single neurosphere was placed into Matrigel, and GFAP (green), respectively, immunoreactive cells in the control (F,H,K,M) and Cerebrolysin (10 ll/ml in G,L and 20 ll/ml in I,N) groups. E,J,O: Quantitative data of BrdU-, Tuj1-, and GFAP-positive cells. P,R: Representative migration of neural progenitor cells out of a neurosphere in the control (P) and Cerebrolysin (20 ll/ml, R) groups. S: Quantitative migration data. T: Western blots and quantitative data. *P < 0.05 vs the control group. n 5 6/group. C, control; CBL, Cerebrolysin; LY, LY294002. Scale bar 5 20 lm.
neural progenitor cells migrated out of the neurosphere (Robin et al., 2006) . Distances of the cells that migrated out of the neurosphere were recorded 72 hr after incubation. Cerebrolysin at 20 ll/ml significantly increased migration distance compared with the distance in the control group (Fig. 3P-S) , indicating that Cerebrolysin promotes progenitor migration.
The PI3K/Akt pathway mediates neurogenesis (Katakowski et al., 2003; Wang et al., 2005; MairetCoello et al., 2009) . To examine whether Cerebrolysin activates this pathway, we performed Western blots. Incubation of SVZ neural progenitor cells with Cerebrolysin at 10 ll/ml substantially increased phosphorylated Akt, whereas a PI3K/Akt inhibitor, LY294002, suppressed Cerebrolysin-elevated phosphorylated Akt (Fig.  3T) . Moreover, although Cerebrolysin significantly increased progenitor cell proliferation (43.6% 6 3% of BrdU 1 cells, n 5 6) compared with the control group (27.1% 6 3.3% of BrdU 1 cells, n 5 6), Cerebrolysinaugmented cell proliferation was abolished by LY294002 (29.7% 6 4% of BrdU 1 cells, n 5 6).
DISCUSSION
The present study demonstrates that Cerebrolysin dose dependently improved neurological outcome when administered 24 and 48 hr after stroke. In vivo and in vitro data show that Cerebrolysin substantially augmented neurogenesis in the ischemic brain and did not reduce the ischemic lesion. Therefore, our data suggest that neurogenesis increased by Cerebrolysin may contribute to the improved functional outcomes.
Stroke stimulates neurogenesis in the SVZ and newly generated neuroblasts in the SVZ migrate to the ischemic boundary region (Jin et al., 2001; Zhang et al., 2001; Arvidsson et al., 2002) . The present study indicates that Cerebrolysin augments neurogenesis in the ischemic SVZ and striatal boundary region. Neurogenesis enhanced by Cerebrolysin is likely involved in multiple mechanisms. Cerebrolysin treatment substantially reduced the TUNEL-positive cells in the ischemic boundary but not in the SVZ, suggesting that Cerebrolysin attenuates neuroblast apoptosis. Cerebrolysin can enhance hippocampal neurogenesis by augmenting survival of the hippocampal neural progenitor cells (Tatebayashi et al., 2003; Rockenstein et al., 2007) . In addition, our in vitro data indicate that, in the presence of the bFGF and EGF, Cerebrolysin promotes neural progenitor cell proliferation measured by an increase in the number of BrdU 1 cells. The effect of Cerebrolysin on cell proliferation is specific, because the nonischemic and ischemic neural progenitor cells exhibited different dose responses to Cerebrolysin-enhanced cell proliferation. Furthermore, Cerebrolysin enhances the ischemic neural progenitor cell differentiation into neurons. These findings are consistent with studies in adult hippocampal neural progenitor cells, which show that Cerebrolysin increases neural progenitor cell proliferation and neuronal differentiation (Chen et al., 2007) . Thus, in addition to augmentation of neural progenitor cell survival, Cerebrolysin can promote neurogenesis by directly acting on enhancement of proliferation and differentiation of SVZ neural progenitor cells.
The present in vivo data show that Cerebrolysin substantially increased DCX-positive cells in the ischemic boundary region. DCX-positive cells are migrating neuroblasts and are generated in the SVZ (AlvarezBuylla et al., 2000) . Under physiological condition, these neuroblasts migrate to the olfactory bulb, where they differentiate into neurons (Alvarez-Buylla et al., 2000) . After focal cerebral ischemia, neuroblasts in the SVZ migrate to the ischemic boundary region to replace damaged neurons (Jin et al., 2001; Zhang et al., 2001; Arvidsson et al., 2002) . Our in vitro data indicate that Cerebrolysin has a direct effect on promoting neural progenitor cell migration. Together with in vivo results, the present study suggests that, in addition to an increase in the number of neuroblasts, Cerebrolysin may promote SVZ neuroblast migration to the ischemic boundary.
The neuropeptide mixture Cerebrolysin has neurotrophic effects in vivo and in vitro (Chen et al., 2007) , which could contribute to the enhanced neurogenesis observed in the present study. Cerebrolysin contains peptides with ciliary neurotrophic factor (CNTF) and other trophic activities, but not the intact proteins (Chen et al., 2007) . Blockage of CNTF abolishes Cerebrolysin-induced neurogenesis in adult hippocampal neural progenitor cells (Chen et al., 2007) , indicating that CNTF in Cerebrolysin plays a major role in promoting neurogenesis (Chen et al., 2007) . CNTF induces neurogenesis and gliogenesis (Chen et al., 2007; Nagao et al., 2007) . In vitro, CNTF along with Notch signals or in the presence of bFGF facilitates generation of astrocytes in the SVZ neural progenitor cells (Nagao et al., 2007) . In addition to neurotrophic factors, Cerebrolysin modulates glycogen synthase kinase-3b (GSK3b)-and cyclin-dependent kinase-5 (CDK5)-dependent phosphorylation (Rockenstein et al., 2007) . GSK3b is a well-characterized Akt substrate (Vojtek et al., 2003) . The PI3K/Akt pathway regulates cell proliferation, survival, and migration (Vojtek et al., 2003; Wang et al., 2005) . We previously demonstrated that activation of the PI3K/Akt pathway promotes SVZ neural progenitor cell proliferation, differentiation, and migration (Katakowski et al., 2003; Wang et al., 2005 ). The present study shows that Cerebrolysin activated Akt in SVZ neural progenitor cells and that blockage of the PI3K/ Akt pathway with LY294002 abolished Cerebrolysinincreased cell proliferation. Thus, our data suggest that the PI3K/Akt pathway plays an important role in Cerebrolysin-enhanced neurogenesis.
Our data show that treatment with Cerebrolysin initiated 24 and 48h after stroke significantly improved functional outcome but did not substantially reduce the infarction, which is consistent with previous findings (Ren et al., 2007) . Augmentation of proliferation, migra-tion, and survival of neuroblasts may contribute to the observed improvement of functional outcome.
